Market Outlook

By 2032, the U.S. Ambulatory Respiratory Care Devices Market is projected to reach approximately USD 24.34 billion, expanding at a CAGR of approximately 11.2% during the forecast period 2027–2032. The market generated approximately USD 11.75 billion in 2025, compared with USD 10.78 billion in 2024 and USD 9.86 billion in 2023. The base year for the report is 2026, while historical analysis covers 2023–2025. All monetary values are expressed in USD billions.

The U.S. ambulatory respiratory care devices industry is evolving from a traditional durable medical equipment market into a connected, therapy-management ecosystem spanning sleep-disordered breathing, chronic obstructive pulmonary disease, asthma, chronic respiratory failure, oxygen-dependent lung disease, bronchiectasis, cystic fibrosis, neuromuscular respiratory impairment, and post-acute respiratory recovery.

This transformation is being driven by several overlapping forces. Chronic respiratory disease remains prevalent across the United States; the population aged 65 and older continues to expand; obstructive sleep apnea remains materially underdiagnosed; hospitals are under pressure to discharge appropriate respiratory patients earlier; and payers increasingly favor therapies that can be delivered safely outside high-cost inpatient settings. At the same time, respiratory devices are becoming lighter, quieter, software-connected, battery powered, algorithmically adaptive, and easier for patients and caregivers to operate.

Nearly 27.8 million Americans had current asthma in 2023, including approximately 23.0 million adults. Diagnosed COPD affected approximately 3.8% of U.S. adults on an age-adjusted basis in 2023, rising sharply with age and reaching 10.5% among adults aged 75 years and older. More than 1.5 million U.S. adults have historically been reported to use supplemental oxygen, while obstructive sleep apnea is believed to affect nearly 30 million U.S. adults. These patient pools create recurring demand for positive airway pressure systems, oxygen concentrators, nebulizers, respiratory assist devices, portable ventilators, airway-clearance technologies, masks, accessories, monitoring devices, and connected respiratory platforms.

Historical growth from USD 9.86 billion in 2023 to USD 11.75 billion in 2025 was supported by sleep therapy replacement demand, increased adoption of portable oxygen concentrators, greater home respiratory monitoring, recovery of DME supply channels, expansion of airway-clearance therapy, and the migration of respiratory management toward the home.

Through 2032, value creation will increasingly come from devices that combine effective therapy with mobility, adherence monitoring, automated titration, remote connectivity, compact form factors, and lower total cost of care. Manufacturers capable of connecting the device, patient, respiratory therapist, DME supplier, prescribing physician, and payer within one clinical workflow will hold a structural advantage over suppliers competing mainly on hardware price.

 

Introduction

According to the U.S. Ambulatory Respiratory Care Devices Market Report, ambulatory respiratory care occupies an increasingly important position between acute hospital respiratory therapy and routine pharmaceutical disease management.

The market covers respiratory devices intended primarily for use in homes, sleep centers, pulmonary clinics, physician practices, outpatient departments, long-term care environments, post-discharge programs, and other non-intensive-care settings. The report scope includes positive airway pressure equipment and interfaces, oxygen therapy systems, nebulizers, respiratory assist and selected home ventilation devices, airway-clearance systems, portable respiratory technologies, pulse oximetry and respiratory monitoring products, and supporting digital connectivity.

The central economic proposition is straightforward: respiratory disease frequently requires long-duration treatment, but a large portion of that treatment does not need an inpatient bed. Appropriate technology can transfer therapy into the patient’s normal living environment while maintaining clinician oversight.

That transition matters because chronic respiratory patients often generate recurring utilization through exacerbations, emergency department visits, hospitalizations, repeat diagnostic testing, and post-acute care. Devices that improve treatment adherence, enable earlier intervention, facilitate mobility, or prevent avoidable deterioration therefore have value beyond their acquisition price.

Sleep respiratory care represents an especially important commercial pillar. Nearly 30 million U.S. adults are believed to have obstructive sleep apnea, with a large portion remaining undiagnosed. Positive airway pressure therapy creates a recurring economic ecosystem involving therapy devices, masks, tubing, humidification, replacement accessories, connectivity, adherence management, and DME services. The result is a revenue pool in which installed-device growth is reinforced by recurring consumable replacement.

Oxygen therapy has a different economic structure but similar ambulatory momentum. Traditional stationary concentrators and compressed oxygen remain important, yet portable oxygen concentrators continue to alter patient expectations. Patients increasingly seek systems that support mobility, vehicle use, air travel, rehabilitation, and normal daily activity rather than equipment that confines therapy to a single location.

The market is also shaped by Medicare and DME economics. Oxygen equipment, CPAP systems, respiratory assist devices, nebulizers, and selected respiratory products fall within established DME pathways when applicable coverage conditions are met. As a result, reimbursement documentation, supplier accreditation, therapy adherence, servicing obligations, replacement schedules, and physician documentation materially influence commercial success.

The underlying opportunity is therefore not simply rising respiratory prevalence. It is the restructuring of respiratory care around lower-acuity settings, longitudinal monitoring, patient mobility, and measurable therapy adherence.

 

Key Market Drivers: What’s Fueling the U.S. Ambulatory Respiratory Care Devices Market Boom?

The first major driver is the size and persistence of chronic respiratory disease. Approximately 27.8 million people in the United States were living with current asthma in 2023. COPD prevalence increases materially with age, making demographic aging a direct respiratory-device demand driver. Among adults aged 45 and older, COPD prevalence is substantially higher in nonmetropolitan populations than in large urban centers, creating particular need for home therapy and remote respiratory management in rural markets.

The second driver is obstructive sleep apnea underdiagnosis. Nearly 30 million U.S. adults are believed to have OSA, while a large majority of cases historically have remained undiagnosed. Wider screening by primary care, cardiology, obesity medicine, bariatric care, and home sleep testing can enlarge the treated population. Every incremental diagnosis potentially creates demand for PAP hardware, patient interfaces, replacement masks, accessories, adherence software, and DME services.

A third growth engine is the outpatientization of chronic respiratory care. Hospitals increasingly seek to discharge clinically stable patients into home-based therapy programs when oxygen, non-invasive ventilation, secretion clearance, nebulized medication, or monitoring can be safely managed outside the inpatient environment. For health systems, successful respiratory discharge programs can improve bed availability and reduce unnecessary inpatient days. For manufacturers, they expand the addressable market from an institutional purchasing model into longitudinal home therapy.

The fourth driver is the increasing importance of mobility. Portable oxygen concentrators, smaller respiratory assist systems, wearable airway-clearance products, compact nebulizers, battery-powered devices, and travel-oriented PAP equipment have changed patient expectations. Mobility is not merely a convenience feature. For many COPD and oxygen-dependent patients, the ability to leave the home can influence physical activity, social participation, rehabilitation compliance, and quality of life.

A fifth driver is connectivity. Respiratory therapy increasingly involves cloud-based adherence tracking, device-status monitoring, prescription settings, therapy-hour records, remote troubleshooting, patient engagement, and risk stratification. DME suppliers value connectivity because it can reduce unnecessary service calls and identify adherence problems earlier. Clinicians value it because they can review therapy without requiring every patient to return physically to the clinic.

A sixth driver is the economics of recurring consumables. Unlike many capital medical-device markets, respiratory care combines durable equipment with high-frequency replacement products. PAP masks, cushions, filters, circuits, tubing, humidification accessories, nebulizer components, cannulas, batteries, airway-clearance garments, and related supplies create recurring revenue after initial device placement.

A seventh driver is U.S. demographic aging. Respiratory impairment becomes more prevalent with age, and the growth of the Medicare-age population supports demand for oxygen therapy, PAP, COPD management, non-invasive ventilation, monitoring, and post-hospital respiratory services. States such as Florida and Maine already have particularly high proportions of residents aged 65 and older, creating strong structural demand.

Finally, hospital and payer purchasing behavior is shifting toward economic evidence. Manufacturers increasingly need to show that a respiratory device improves adherence, reduces exacerbations, supports timely discharge, minimizes service burden, or decreases avoidable utilization. Product performance remains essential, but performance alone is no longer sufficient.

 

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in ambulatory respiratory care is increasingly centered on patient independence rather than simply respiratory output.

Portable oxygen illustrates this transition. Current-generation concentrators emphasize reduced weight, longer battery life, sensitive breath detection, adaptive oxygen delivery, quieter operation, connected monitoring, and travel suitability. Some systems can automatically adjust oxygen-delivery behavior in response to respiratory patterns, reducing the operational burden placed on the patient.

Sleep therapy is undergoing a similar transformation. PAP systems increasingly incorporate auto-adjusting pressure, cellular or wireless connectivity, adherence analytics, simplified setup, heated humidification, event detection, and cloud-based patient management. Mask innovation remains commercially important because interface discomfort and leakage continue to be major reasons for therapy abandonment.

Home ventilation and respiratory-assist devices are becoming smaller and increasingly suitable for mobility. Patients with neuromuscular disease, chronic respiratory failure, restrictive lung disorders, or advanced COPD can require substantial ventilatory support but may still benefit from technologies designed around life outside the hospital.

Nebulizer innovation is moving toward compact mesh technologies, shorter treatment times, quieter operation, and improved aerosol efficiency. This is particularly relevant to patients with asthma, COPD, bronchiectasis, cystic fibrosis, or other diseases requiring repeated inhaled therapy.

Airway-clearance technologies are also evolving. Traditional high-frequency chest-wall oscillation systems remain important, while newer systems emphasize portability, garment comfort, simplified controls, and the ability to perform therapy while the patient remains active. Mechanical insufflation-exsufflation, oscillatory therapy, positive expiratory pressure, and integrated nebulization further broaden the category.

Digital respiratory care represents the most important cross-category innovation layer. Device connectivity can support adherence management, remote setup, supply replenishment, therapy optimization, reimbursement documentation, and population-level management.

The commercial implication is significant. The competitive unit is no longer only the respiratory device. Increasingly, it is the entire therapy platform.

 

Segmentation Insights

The U.S. Ambulatory Respiratory Care Devices Market is segmented on the basis of product category, care modality, application, end user, technology type, and region.

 

• By Product Category

Positive Airway Pressure Systems, Interfaces and Sleep Respiratory Products

PAP systems and associated sleep respiratory products represented approximately USD 4.15 billion in 2025, making this the largest product category. The segment includes CPAP, APAP, bilevel PAP systems, humidification, nasal masks, full-face masks, nasal-pillow interfaces, tubing, filters, cushions, and supporting adherence platforms.

Commercial strength is supported by an OSA population approaching 30 million adults and continued diagnosis expansion. Replacement masks and accessories provide an attractive recurring-revenue component, while cloud-connected PAP platforms give manufacturers and DME providers continuous relationships with users after initial device placement.

Oxygen Therapy Devices

Oxygen therapy products accounted for approximately USD 2.40 billion in 2025. The category encompasses stationary concentrators, portable oxygen concentrators, oxygen-conserving devices, cylinders and selected accessories.

More than 1.5 million adults have historically used supplemental oxygen in the United States. Portable concentrators are the strongest structural growth area because they address patient mobility and reduce dependence on delivered cylinders. Demand is strongest among COPD, interstitial lung disease, chronic hypoxemia, post-acute respiratory and selected cardiopulmonary patients.

Nebulizers and Aerosol Delivery Devices

Nebulizers and ambulatory aerosol-delivery systems represented approximately USD 1.38 billion in 2025. Compressor nebulizers remain widely used, but mesh and compact electronic nebulizers are gaining share where treatment time, noise, portability, and aerosol performance matter.

The approximately 27.8 million U.S. residents living with current asthma provide a large underlying treatment pool, although only a portion use nebulized therapy. COPD, bronchiectasis and cystic fibrosis further expand the clinical opportunity.

Home Ventilation and Respiratory Assist Devices

Home and ambulatory ventilation and respiratory-assist technologies contributed approximately USD 1.12 billion in 2025. The category includes non-invasive ventilatory support, bilevel respiratory assist devices and selected portable or home mechanical ventilators.

Demand is concentrated in chronic hypercapnic respiratory failure, advanced COPD, neuromuscular disorders, restrictive thoracic disease and other conditions where long-duration ventilatory support can be managed outside acute care.

Airway Clearance Devices

Airway-clearance technologies generated approximately USD 0.92 billion in 2025. High-frequency chest-wall oscillation systems, mechanical cough-assist devices, oscillatory technologies and other secretion-mobilization systems form the core of this segment.

Bronchiectasis, cystic fibrosis, neuromuscular weakness and other mucus-retention disorders support demand. The growth opportunity is increasingly linked to lighter equipment, improved garments, easier controls and home-based adherence.

Ambulatory Respiratory Monitoring and Diagnostic Devices

Portable monitoring and respiratory assessment products accounted for approximately USD 1.78 billion in 2025. The segment includes pulse oximetry, ambulatory respiratory monitoring, portable spirometry, selected capnography applications, sleep-related monitoring and connected respiratory sensors.

Growth is being supported by remote patient monitoring, telehealth, earlier discharge and greater interest in detecting respiratory deterioration before emergency intervention is required.

 

• By Care Modality

Positive Airway Pressure Therapy

Positive airway pressure therapy represented approximately USD 4.00 billion in 2025. It remains the largest ambulatory respiratory therapy modality because OSA generally requires long-term treatment and produces recurring mask and accessory demand.

Adherence remains the central value driver. Devices and interfaces that increase nightly use, reduce leak, simplify setup and allow remote troubleshooting can generate value simultaneously for patients, DME providers and payers.

Oxygen Supplementation

Ambulatory and home oxygen supplementation represented approximately USD 2.40 billion in 2025. Traditional continuous-flow systems remain clinically necessary for some patients, while pulse-dose portable concentrators are expanding the mobility-oriented portion of the market.

Aerosol Drug Delivery

Aerosol-delivery modalities generated approximately USD 1.38 billion in 2025. This segment benefits from recurring use among chronic pulmonary patients requiring nebulized bronchodilators, inhaled antibiotics, saline or other respiratory therapies.

Ventilatory Support

Home and ambulatory ventilatory support represented approximately USD 1.12 billion in 2025. Growth is supported by improved portability and greater clinical confidence in managing selected ventilator-dependent or ventilation-assisted patients outside hospitals.

Secretion Mobilization and Airway Clearance

Secretion-management modalities represented approximately USD 0.92 billion in 2025. The category is smaller than PAP or oxygen but has comparatively strong clinical specialization and premium-device economics.

Monitoring and Respiratory Assessment

Monitoring and assessment technologies represented approximately USD 1.93 billion in 2025 when respiratory monitoring functions embedded across ambulatory systems are included. Pulse oximetry remains the largest installed technology, while connected monitoring provides the strongest future growth opportunity.

 

• By Application

Obstructive Sleep Apnea and Sleep-Disordered Breathing

Sleep-disordered breathing represented approximately USD 4.25 billion in 2025, making it the largest clinical application. With nearly 30 million U.S. adults believed to have OSA and many cases undiagnosed, diagnosis expansion remains a significant market-access opportunity.

Chronic Obstructive Pulmonary Disease

COPD-related respiratory care accounted for approximately USD 2.70 billion in 2025. Diagnosed COPD prevalence was approximately 3.8% among U.S. adults in 2023 and increases markedly with age. COPD supports demand across oxygen therapy, nebulization, non-invasive ventilation, monitoring, airway clearance and post-discharge programs.

Rural COPD is strategically important because prevalence among older adults is materially higher in nonmetropolitan areas. Technologies capable of operating reliably with limited local specialist access therefore have particular value.

Asthma

Asthma applications represented approximately USD 1.50 billion in 2025. Approximately 27.8 million Americans had current asthma in 2023, including 23.0 million adults and 4.8 million children.

The ambulatory device opportunity is concentrated in nebulization, respiratory monitoring, selected spirometry and connected management rather than the pharmaceutical inhaler market covered separately from this report scope.

Chronic Respiratory Failure and Neuromuscular Disease

This application generated approximately USD 1.15 billion in 2025. Although the patient population is smaller, equipment intensity is high. Respiratory-assist devices, home ventilation, cough-assist technology, oxygen and monitoring can generate substantial value per patient.

Bronchiectasis and Cystic Fibrosis

Bronchiectasis, cystic fibrosis and secretion-retention disorders accounted for approximately USD 0.85 billion in 2025. These patients are particularly relevant to airway-clearance systems and advanced aerosol-delivery technologies because therapy may be required repeatedly over many years.

Post-Discharge and Other Chronic Respiratory Care

Other ambulatory and post-acute respiratory applications represented approximately USD 1.30 billion in 2025. This category includes temporary home oxygen, respiratory monitoring, selected post-pneumonia support, post-surgical respiratory management and other lower-acuity respiratory pathways.

 

• By End User

Home Healthcare and Patient Self-Management

Home-based respiratory care represented approximately USD 7.35 billion in 2025, making it the dominant care setting. PAP therapy, oxygen, nebulization, airway clearance and long-duration respiratory support are fundamentally home-oriented treatment categories.

Products that minimize setup complexity, noise, maintenance, caregiver burden and physical footprint are better suited to this setting.

Sleep Centers and Pulmonary Clinics

Sleep centers and pulmonary specialty practices accounted for approximately USD 1.35 billion in 2025. These facilities strongly influence device selection through diagnosis, titration, prescribing, patient education and follow-up.

Hospital Outpatient and Discharge Programs

Hospital outpatient departments and structured respiratory discharge programs represented approximately USD 1.10 billion in 2025. Their strategic importance is higher than their direct revenue share because hospital discharge decisions frequently determine which home respiratory technologies patients adopt.

Skilled Nursing and Long-Term Care

Long-term care and skilled nursing environments contributed approximately USD 0.80 billion in 2025. Older and medically complex residents create demand for oxygen, PAP, nebulization, oximetry, secretion management and non-invasive respiratory support.

Physician Offices and Other Ambulatory Facilities

Physician practices, urgent care and other ambulatory sites represented approximately USD 0.65 billion in 2025, primarily through portable monitoring, diagnostic respiratory equipment, nebulization and therapy-management devices.

Remote Patient Monitoring Programs

Dedicated connected respiratory monitoring programs represented approximately USD 0.50 billion in 2025. This remains a smaller direct revenue category but is expected to expand rapidly as monitoring becomes embedded within respiratory equipment rather than purchased as an independent device.

 

• By Technology Type

Connected and Cloud-Enabled Respiratory Devices

Connected respiratory systems represented approximately USD 3.10 billion in 2025. PAP is the most mature connected category, but oxygen, ventilation and remote monitoring are moving in the same direction.

Portable and Battery-Powered Technologies

Portable and battery-powered devices represented approximately USD 2.85 billion in 2025. Portable oxygen concentrators, travel PAP, compact nebulizers, wearable airway-clearance systems and mobile respiratory monitoring are expanding this segment.

Conventional Electromechanical Devices

Conventional devices represented approximately USD 2.35 billion in 2025. Their share is gradually declining, but they remain important because reliability, low acquisition cost and simple servicing remain priorities for many DME suppliers.

Algorithm-Adaptive and Smart Therapy Systems

Algorithm-enabled systems accounted for approximately USD 1.80 billion in 2025. Auto-adjusting PAP, intelligent oxygen delivery, adaptive ventilation and automated therapy-management functions are the main growth areas.

Wearable and Sensor-Based Respiratory Technologies

Wearable or sensor-centric respiratory products generated approximately USD 1.65 billion in 2025. The segment includes ambulatory oximetry and emerging connected respiratory measurements, with growing relevance to chronic-disease monitoring and post-discharge care.

 

Regional Insights: Where the Market is Growing Fastest

The U.S. Ambulatory Respiratory Care Devices Market is geographically divided into the South, West, Northeast and Midwest. Regional performance differs according to population growth, age distribution, COPD burden, asthma prevalence, smoking history, obesity and sleep-apnea risk, rurality, DME network density, Medicare enrollment and health-system concentration.

The South is the largest market, while the West is expected to post the strongest technology-led growth rate. The Northeast remains a high-value market for sophisticated respiratory therapy and integrated care, while the Midwest combines significant chronic respiratory burden with a large and mature home-DME infrastructure.

South

The South represented approximately USD 4.35 billion in 2025, or about 37% of U.S. ambulatory respiratory care device revenue. The region includes Alabama, Arkansas, Delaware, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, West Virginia and the District of Columbia.

Several structural factors explain this leadership: the South contains some of the fastest-growing states in the country, includes large Medicare populations, carries substantial COPD and cardiometabolic disease burden, and has large rural territories where home therapy can reduce travel to specialist centers.

Texas is a core demand center. Its population reached approximately 31.7 million in 2025, making it the second-largest state in the country. Houston, Dallas–Fort Worth, San Antonio and Austin contain major health systems, pulmonary groups, sleep laboratories and DME networks. Population growth also expands the absolute sleep-apnea and asthma treatment pools even though Texas has a younger demographic profile than Florida.

Florida is particularly important because its population exceeds 23 million and approximately 22.8% of residents are aged 65 or older. The combination of age, Medicare exposure, COPD, sleep-disordered breathing and cardiopulmonary comorbidity creates substantial demand for PAP, oxygen concentrators, nebulizers and monitoring. Portable oxygen is particularly relevant because mobility and retirement lifestyles influence product preference.

North Carolina and Georgia are attractive growth states due to population expansion and strong academic and integrated health systems. North Carolina exceeded 11.1 million residents in 2025, while Georgia surpassed 11.3 million. These markets support both traditional DME demand and newer connected respiratory-management models.

Kentucky and West Virginia are smaller in population but strategically important because chronic respiratory burden, tobacco exposure and rural access challenges increase respiratory-care intensity. Tennessee, Alabama, Mississippi, Louisiana, Arkansas and Oklahoma similarly support strong COPD-oriented demand.

Virginia and Maryland have comparatively sophisticated provider networks, making them relevant for connected PAP, home ventilation and digitally managed respiratory therapy.

By 2032, the South is projected to generate approximately USD 9.05 billion, retaining its position as the country’s largest regional market.

West

The West accounted for approximately USD 2.62 billion in 2025 and is expected to register the fastest overall expansion through 2032. It includes California, Washington, Oregon, Arizona, Nevada, Colorado, Utah, New Mexico, Idaho, Montana, Wyoming, Alaska and Hawaii.

California is the anchor market. With approximately 39.4 million residents in 2025, it remains the largest U.S. state and combines a very large respiratory patient base with a sophisticated digital-health and medical-technology ecosystem. California providers are particularly receptive to connected PAP management, digital respiratory monitoring and outpatient chronic-care models where clinical and economic evidence supports adoption.

Arizona and Nevada are important growth markets because of population expansion and large retirement communities. Their climate, population migration and aging demographics create meaningful oxygen and sleep respiratory demand.

Washington, Oregon and Colorado have health systems that are relatively advanced in digital integration and value-based care. These characteristics favor respiratory devices capable of remote adherence monitoring, therapy analytics and electronic workflow integration.

Utah and Idaho are smaller but fast-growing population markets. New Mexico, Montana, Wyoming and Alaska have lower population density, giving portability and remote respiratory management particular importance because specialist access can require long travel distances.

Hawaii presents a distinct logistical environment in which compact and service-efficient equipment is economically advantageous.

The West is projected to reach approximately USD 5.75 billion by 2032. Its growth will be driven disproportionately by connected respiratory platforms, portable technologies, direct-to-patient engagement and digitally coordinated chronic-care models.

Northeast

The Northeast represented approximately USD 2.45 billion in 2025. The region includes New York, Pennsylvania, New Jersey, Massachusetts, Connecticut, Rhode Island, Maine, New Hampshire and Vermont.

New York is the region’s largest commercial market, supported by a population of approximately 20.0 million in 2025, dense pulmonary and sleep-medicine networks and major integrated health systems. High patient density facilitates DME logistics and recurring supply distribution.

Pennsylvania and New Jersey provide significant PAP, oxygen, COPD and long-term-care demand. Pennsylvania’s aging population and mixture of major metropolitan centers and rural communities creates a broad device requirement ranging from connected sleep platforms to oxygen and respiratory support.

Massachusetts has outsized influence relative to its population because of academic medicine, respiratory research, digital-health adoption and concentrated specialty care. New clinical approaches evaluated at large academic centers can subsequently influence broader national adoption.

Maine is noteworthy because approximately 24.6% of its residents are aged 65 or older, among the highest state shares nationally. Although the state is small in absolute population, aging and rurality increase the importance of home oxygen, PAP and remotely supported respiratory therapy.

Connecticut, Rhode Island, New Hampshire and Vermont add smaller but relatively high-value markets characterized by insured populations and established pulmonary and sleep networks.

The Northeast is projected to approach USD 4.95 billion by 2032. Growth will be slower than the West on a percentage basis but supported by premium technology adoption, replacement demand and sophisticated homecare infrastructure.

Midwest

The Midwest accounted for approximately USD 2.33 billion in 2025. The region comprises Illinois, Indiana, Michigan, Ohio, Wisconsin, Minnesota, Iowa, Missouri, Kansas, Nebraska, North Dakota and South Dakota.

Illinois is the largest regional market, with approximately 12.7 million residents in 2025, and Chicago provides a major concentration of academic hospitals, sleep clinics, pulmonary practices and DME suppliers.

Ohio and Michigan are substantial respiratory-device markets because of their population scale, industrial smoking legacy, chronic disease burden and mature hospital networks. Ohio approached 11.9 million residents in 2025 and Michigan exceeded 10.1 million, creating large bases for PAP, COPD therapy, oxygen and nebulization.

Minnesota combines a strong healthcare delivery environment with a major medical-device ecosystem, making the state important for both adoption and innovation. Wisconsin, Indiana and Missouri provide stable home respiratory demand and significant Medicare exposure.

Iowa, Kansas, Nebraska, North Dakota and South Dakota have smaller absolute markets but comparatively large rural populations. Remote therapy monitoring, portable oxygen and reliable home equipment have particular value where patients may live far from tertiary pulmonary centers.

By 2032, the Midwest is projected to generate approximately USD 4.59 billion. The region is likely to grow more steadily than the West or South, but its mature DME channels and significant chronic respiratory burden make it a durable market.

 

Key Market Players

The U.S. Ambulatory Respiratory Care Devices Competitive Landscape is concentrated in several high-value categories but remains fragmented across oxygen therapy, sleep respiratory care, ventilation, aerosol delivery, airway clearance and monitoring.

Scale advantages come from installed device bases, recurring consumables, clinician relationships, payer access, DME contracting, servicing infrastructure and connected software platforms. Product reliability is particularly important because failures in home respiratory therapy can carry significant clinical and operational consequences.

Some of the most relevant companies in the U.S. Ambulatory Respiratory Care Devices Market are:

ResMed
Fisher & Paykel Healthcare
Philips Respironics
Inogen
CAIRE Inc.
React Health
Drive DeVilbiss Healthcare
Breas Medical
Baxter International / Hillrom Respiratory Health
PARI Respiratory Equipment
Aerogen
Electromed
Masimo
Nonin Medical
Nidek Medical Products

ResMed holds a particularly strong position in sleep and breathing health through PAP systems, masks, connected care and respiratory support. Its scale illustrates the economic depth of the category: U.S. corporate revenue exceeded USD 3.5 billion in its fiscal year ending June 2026, while its broader Americas sleep and breathing portfolio continued to expand.

Fisher & Paykel Healthcare is an important competitor in respiratory interfaces and homecare. Its global Homecare business exceeded USD 800 million in fiscal 2026, with recent mask platforms supporting OSA growth.

The U.S. sleep respiratory competitive structure has also been materially affected by regulatory developments surrounding Philips Respironics, creating opportunities for competitors to gain device placements, DME relationships and recurring mask share.

In oxygen therapy, Inogen, CAIRE, Drive DeVilbiss, React Health and Nidek compete around portability, flow capability, reliability, weight, battery duration, DME economics and service requirements.

Baxter/Hillrom and Electromed have relevant positions in airway clearance, while Breas participates in home and portable ventilation. PARI and Aerogen contribute specialized aerosol-delivery technologies. Masimo and Nonin are important participants in respiratory monitoring and pulse-oximetry-related workflows.

Future market share will increasingly depend on how successfully companies combine hardware reliability with patient adherence, digital visibility, DME economics and clinical workflow integration.

 

Recent Developments

Recent developments demonstrate how quickly the U.S. ambulatory respiratory care competitive environment is changing.

During fiscal 2026, ResMed reported continued growth across sleep and breathing health, with Americas sleep and breathing revenue exceeding USD 3.28 billion and U.S. company revenue exceeding USD 3.56 billion. Device and mask growth confirms that sleep respiratory therapy continues to provide a large recurring U.S. revenue pool.

Fisher & Paykel Healthcare reported approximately USD 802.7 million in global Homecare revenue for fiscal 2026, an 8% increase from the prior year. Its newer OSA mask ranges supported growth, and the F&P Nova Nasal was introduced into the United States during 2026.

The portable oxygen category also continues to innovate. CAIRE introduced an updated FreeStyle Comfort portable oxygen concentrator with adaptive oxygen-delivery functionality into the U.S. market in October 2025, reinforcing the industry’s movement toward responsive therapy and mobility.

Inogen generated approximately USD 348.7 million in 2025 revenue and reported sales of roughly 189,400 oxygen systems, an increase of more than 20% from the prior year. The data demonstrate continuing unit demand for oxygen equipment even as manufacturers diversify beyond traditional concentrator platforms.

The FDA also continues to clear new portable oxygen technologies, expanding competition and increasing buyer choice. This dynamic places pressure on incumbent manufacturers to differentiate through service quality, battery performance, weight, reliability, telehealth connectivity and DME-friendly economics.

Airway clearance has experienced product modernization as well. Baxter introduced its next-generation Vest APX airway-clearance system, emphasizing patient comfort, user-interface improvements and home therapy.

One of the most consequential competitive events remains the Philips Respironics regulatory situation. A 2024 federal consent decree restricted, with limited exceptions, production and sale of certain new CPAP, BiPAP and other respiratory devices at designated U.S. facilities until specified regulatory requirements are met. The disruption altered competitive procurement dynamics across sleep respiratory care and provided competing manufacturers with opportunities to expand installed bases.

These developments reinforce a broader conclusion: ambulatory respiratory care is shifting away from stand-alone durable hardware toward connected, patient-centered therapy ecosystems.

 

Conclusion

The U.S. Ambulatory Respiratory Care Devices Market Size & Share is positioned for strong expansion through 2032, supported by chronic respiratory disease, population aging, underdiagnosed sleep-disordered breathing, hospital-to-home migration and rapid innovation in portable and connected respiratory technology.

From approximately USD 9.86 billion in 2023, the market expanded to USD 10.78 billion in 2024 and USD 11.75 billion in 2025. By 2032, market revenue is projected to reach approximately USD 24.34 billion, reflecting a forecast CAGR of approximately 11.2% during 2027–2032.

Sleep and positive airway pressure therapy will remain the largest revenue pool, but oxygen mobility, home ventilation, airway clearance, nebulization and respiratory monitoring will generate meaningful incremental growth.

The strongest device propositions will increasingly combine three attributes: clinical effectiveness, patient usability and economic visibility.

A technically superior respiratory device that patients do not use consistently has limited value. A highly connected device that creates additional workload for clinicians will struggle to scale. A low-cost device that generates service calls or fails prematurely can damage DME economics. Successful manufacturers must optimize all three dimensions simultaneously.

From a care-delivery perspective, home healthcare will remain the dominant setting. Hospital outpatient programs, sleep centers, pulmonary clinics and remote monitoring will nevertheless exert growing influence because they determine patient identification, prescribing, discharge and therapy optimization.

Geographically, the South will remain the largest U.S. regional market, supported by Texas, Florida, Georgia, North Carolina, Tennessee, Virginia and high-burden Appalachian and Gulf states. The West will generate the strongest technology-led growth, particularly in California, Arizona, Washington, Colorado and Nevada. The Northeast will remain a premium adoption market, while the Midwest will provide stable, high-volume respiratory demand supported by large chronic disease populations and established DME infrastructure.

For device manufacturers, investors, DME suppliers and health systems evaluating this market, the critical strategic question is therefore not simply how many respiratory patients will require devices. It is how rapidly respiratory therapy will shift toward portable, connected and remotely supervised models—and which manufacturers can create an economic advantage across the complete therapy pathway.

The companies positioned to outperform through 2032 will be those capable of integrating device engineering, recurring consumables, digital adherence management, payer documentation, homecare service efficiency and patient-centered design into a scalable respiratory-care platform.